Limits...
Characteristics of human amniotic fluid mesenchymal stem cells and their tropism to human ovarian cancer.

Li L, Wang D, Zhou J, Cheng Y, Liang T, Zhang G - PLoS ONE (2015)

Bottom Line: We successfully isolated the AFMSCs from thirteen of twenty amniotic fluid samples.RT-PCR results showed that the AFMSCs expressed stem cell marker OCT4.Meanwhile, the research emphasis in the future can also put in targeting therapy of ovarian cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Genecology and Obstetrics, Harbin Medical University, Harbin, Heilongjiang, China.

ABSTRACT
The mesenchymal stem cells (MSCs) derived from amniotic fluid (AF) have become an attractive stem cells source for cell-based therapy because they can be harvested at low cost and avoid ethical disputes. In human research, stem cells derived from AF gradually became a hot research direction for disease treatment, specifically for their plasticity, their reduced immunogenicity and their tumor tropism regardless of the tumor size, location and source. Our work aimed to obtain and characterize human amniotic fluid mesenchymal stem cells (AFMSCs) and detect their ovarian cancer tropsim in nude mice model. Ten milliliters of twenty independent amniotic fluid samples were collected from 16-20 week pregnant women who underwent amniocentesis for fetal genetic determination in routine prenatal diagnosis in the first affiliated hospital of Harbin medical university. We successfully isolated the AFMSCs from thirteen of twenty amniotic fluid samples. AFMSCs presented a fibroblastic-like morphology during the culture. Flow cytometry analyses showed that the cells were positive for specific stem cell markers CD73,CD90, CD105, CD166 and HLA-ABC (MHC class I), but negative for CD 45,CD40, CD34, CD14 and HLA-DR (MHC class II). RT-PCR results showed that the AFMSCs expressed stem cell marker OCT4. AFMSCs could differentiate into bone cells, fat cells and chondrocytes under certain conditions. AFMSCs had the high motility to migrate to ovarian cancer site but didn't have the tumorigenicity. This study enhances the possibility of AFMSCs as drug carrier in human cell-based therapy. Meanwhile, the research emphasis in the future can also put in targeting therapy of ovarian cancer.

No MeSH data available.


Related in: MedlinePlus

The growth curve and PDT of AFMSCs in passage 3,5,10,15 and 20.(A) The growth curve of AFMSCs in different passages. (B) The PDT of AFMSCs in different passages.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4400015&req=5

pone.0123350.g002: The growth curve and PDT of AFMSCs in passage 3,5,10,15 and 20.(A) The growth curve of AFMSCs in different passages. (B) The PDT of AFMSCs in different passages.

Mentions: The cell growth curves at P3,P5,P10,P15 and P20 were shown in Fig 2-1. The growth curves were roughly similar to shape ā€œSā€. The cells stayed in detention period after passaging 2 days, then turned to logarithmic phase and seven days later the cell number no longer increased. The proliferation of cells in tenth generation was slower than in third and fifth generation. The PDT (population double time) of AFMSCs was shown in Fig 2-2. It was determined to be 50, 48, 55,67and 97 h for P3, P5, P10,P15 and P20, respectively.


Characteristics of human amniotic fluid mesenchymal stem cells and their tropism to human ovarian cancer.

Li L, Wang D, Zhou J, Cheng Y, Liang T, Zhang G - PLoS ONE (2015)

The growth curve and PDT of AFMSCs in passage 3,5,10,15 and 20.(A) The growth curve of AFMSCs in different passages. (B) The PDT of AFMSCs in different passages.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4400015&req=5

pone.0123350.g002: The growth curve and PDT of AFMSCs in passage 3,5,10,15 and 20.(A) The growth curve of AFMSCs in different passages. (B) The PDT of AFMSCs in different passages.
Mentions: The cell growth curves at P3,P5,P10,P15 and P20 were shown in Fig 2-1. The growth curves were roughly similar to shape ā€œSā€. The cells stayed in detention period after passaging 2 days, then turned to logarithmic phase and seven days later the cell number no longer increased. The proliferation of cells in tenth generation was slower than in third and fifth generation. The PDT (population double time) of AFMSCs was shown in Fig 2-2. It was determined to be 50, 48, 55,67and 97 h for P3, P5, P10,P15 and P20, respectively.

Bottom Line: We successfully isolated the AFMSCs from thirteen of twenty amniotic fluid samples.RT-PCR results showed that the AFMSCs expressed stem cell marker OCT4.Meanwhile, the research emphasis in the future can also put in targeting therapy of ovarian cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Genecology and Obstetrics, Harbin Medical University, Harbin, Heilongjiang, China.

ABSTRACT
The mesenchymal stem cells (MSCs) derived from amniotic fluid (AF) have become an attractive stem cells source for cell-based therapy because they can be harvested at low cost and avoid ethical disputes. In human research, stem cells derived from AF gradually became a hot research direction for disease treatment, specifically for their plasticity, their reduced immunogenicity and their tumor tropism regardless of the tumor size, location and source. Our work aimed to obtain and characterize human amniotic fluid mesenchymal stem cells (AFMSCs) and detect their ovarian cancer tropsim in nude mice model. Ten milliliters of twenty independent amniotic fluid samples were collected from 16-20 week pregnant women who underwent amniocentesis for fetal genetic determination in routine prenatal diagnosis in the first affiliated hospital of Harbin medical university. We successfully isolated the AFMSCs from thirteen of twenty amniotic fluid samples. AFMSCs presented a fibroblastic-like morphology during the culture. Flow cytometry analyses showed that the cells were positive for specific stem cell markers CD73,CD90, CD105, CD166 and HLA-ABC (MHC class I), but negative for CD 45,CD40, CD34, CD14 and HLA-DR (MHC class II). RT-PCR results showed that the AFMSCs expressed stem cell marker OCT4. AFMSCs could differentiate into bone cells, fat cells and chondrocytes under certain conditions. AFMSCs had the high motility to migrate to ovarian cancer site but didn't have the tumorigenicity. This study enhances the possibility of AFMSCs as drug carrier in human cell-based therapy. Meanwhile, the research emphasis in the future can also put in targeting therapy of ovarian cancer.

No MeSH data available.


Related in: MedlinePlus